BlackRock, Inc. 13D and 13G filings for Fate Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 5:31 pm Unchanged | 2024-09-30 | 13G | Fate Therapeutics, Inc. FATE | BlackRock Inc. BLK | 10,473,250 9.200% | 0 (Unchanged) | Filing |
| 2024-10-21 4:11 pm Sale | 2024-09-30 | 13G | Fate Therapeutics, Inc. FATE | BlackRock Inc. BLK | 10,473,250 9.200% | -739,566 (-6.60%) | Filing |
| 2024-01-24 09:46 am Purchase | 2023-12-31 | 13G | Fate Therapeutics, Inc. FATE | BlackRock Inc. BLK | 11,212,816 11.400% | 1,486,921 (+15.29%) | Filing |
| 2023-01-06 12:23 pm Purchase | 2022-12-31 | 13G | Fate Therapeutics, Inc. FATE | BlackRock Inc. BLK | 9,725,895 10.000% | 2,665,343 (+37.75%) | Filing |
| 2022-02-02 7:11 pm Purchase | 2021-12-31 | 13G | Fate Therapeutics, Inc. FATE | BlackRock Inc. BLK | 7,060,552 7.400% | 389,011 (+5.83%) | Filing |
| 2021-01-29 09:57 am Purchase | 2020-12-31 | 13G | Fate Therapeutics, Inc. FATE | BlackRock Inc. BLK | 6,671,541 7.600% | 878,854 (+15.17%) | Filing |